Obsessive-compulsive disorder traps you in cycles of intrusive thoughts and compulsive behaviors that consume hours of each day. When standard treatments provide only partial relief, the exhaustion and frustration can feel overwhelming. At Mend The Mind, we provide ketamine therapy and comprehensive psychiatric care as adjunctive treatment for adults with treatment-resistant OCD.
Research on ketamine for OCD is preliminary but shows potential for rapid symptom relief in some patients, particularly those with constant intrusive thoughts. Our approach combines ketamine therapy with medication management and therapeutic support to address OCD’s neurobiological and psychological dimensions.
OCD affects approximately 2-3% of the population and involves persistent, intrusive thoughts (obsessions) that create intense anxiety, along with repetitive behaviors or mental rituals (compulsions) performed to reduce that anxiety. The disorder exists on a spectrum from mild to severe, with some people spending hours daily performing rituals while others experience primarily mental compulsions invisible to observers.
Common obsession themes include contamination fears, concerns about harm or danger, need for symmetry or exactness, forbidden or taboo thoughts about sex, religion, or violence, and fears of losing control or acting impulsively. Compulsions often involve washing or cleaning, checking locks, appliances, or safety, counting or repeating actions, arranging items in specific ways, seeking reassurance, and mental rituals like praying or reviewing thoughts.
The defining feature of OCD is that you recognize the thoughts are irrational or excessive, yet cannot stop them through willpower alone. The compulsions provide only temporary relief before anxiety returns, creating self-perpetuating cycles that progressively narrow your life. Activities that once felt natural now require extensive rituals, leaving little time or energy for what actually matters to you.
Treatment-resistant OCD affects approximately one-third of patients—those who don’t achieve adequate symptom relief despite appropriate trials of first-line treatments. Severe OCD can be profoundly disabling, affecting work, relationships, physical health, and creating significant suicide risk.
Standard OCD treatments include serotonin reuptake inhibitors (SSRIs and clomipramine) combined with specialized cognitive behavioral therapy. While these approaches help many patients, approximately 40-60% don’t respond adequately to medication alone. SSRIs require 10-12 weeks at therapeutic doses before showing maximum benefit—longer than for depression—and higher doses are typically needed for OCD, which can increase side effects.
Many people try multiple medications and therapeutic approaches without finding sufficient relief. The waiting period for medications to work creates extended suffering when OCD is severe. Additionally, when OCD symptoms are overwhelming, engaging fully in any treatment becomes difficult—the constant mental intrusion makes it hard to focus, process information, or implement behavioral strategies.
The neurobiology of OCD involves dysregulation in multiple brain systems including serotonin circuits and, emerging evidence suggests, the glutamate system. Traditional treatments targeting serotonin don’t address potential glutamate dysfunction, which may explain why many patients experience only partial response.
Treatment resistance in OCD often leads to progressive functional decline, social isolation, development of comorbid depression or anxiety, and increased suicide risk. Finding effective interventions for severe, resistant cases remains a critical need.
Ketamine’s role in OCD treatment is still being studied, with evidence that is preliminary and mixed. Current research suggests ketamine may provide rapid but temporary relief for some OCD patients, particularly those with constant intrusive thoughts rather than primarily behavioral compulsions.
A 2013 randomized controlled trial found 50% of OCD patients receiving ketamine met criteria for treatment response one week after a single infusion, compared to 0% receiving placebo. Patients reported dramatic decreases in obsessive thoughts during the infusion itself, with some describing the experience as finally being free from the constant mental intrusion.
However, this benefit is typically short-lived, lasting 1-3 weeks without additional treatment. Subsequent research shows similar patterns—rapid anti-obsessional effects that peak within hours of infusion but fade over days to weeks. Not all patients respond, and the degree of response varies considerably.
The mechanism appears to involve ketamine’s effects on glutamate neurotransmission through NMDA receptor antagonism. Converging evidence suggests glutamate dysregulation contributes to OCD pathophysiology, and ketamine may temporarily normalize these circuits. The rapid onset differs dramatically from SSRIs’ 10-12 week timeline.
Research on repeated ketamine treatments for OCD remains limited. Some studies suggest benefits may extend with ongoing infusions, though optimal dosing schedules haven’t been established. The evidence base is much smaller and less robust than ketamine’s evidence for depression or PTSD.
We provide ketamine therapy and psychiatric care as adjunctive treatment for adults with severe, treatment-resistant OCD. Our services focus on what we can offer while being transparent about evidence limitations.
For patients with treatment-resistant OCD who haven’t responded to multiple medication trials, ketamine infusions may provide additional benefit. We use protocols informed by research—typically assessing response across a series of infusions to determine effectiveness for your specific symptom profile.
Each infusion lasts 40-60 minutes under continuous monitoring by our provider who holds dual board certification in both psychiatry and anesthesia. This unique combination of expertise ensures both therapeutic focus and maximum safety during treatment.
Because ketamine’s effects in OCD are often temporary, we work with you to determine appropriate maintenance schedules if initial treatment proves beneficial. Some patients need regular ongoing infusions to sustain symptom reduction, while others find effects last longer between treatments.
We’re transparent about what ketamine can and cannot do for OCD. The evidence is preliminary, effects are often short-lived without maintenance, response rates are variable, and not all symptom profiles respond equally. We carefully assess whether you’re an appropriate candidate based on your treatment history and symptom presentation.
After establishing response to IV ketamine, some patients transition to sublingual ketamine troches for ongoing maintenance. These at-home treatments provide convenient symptom management between IV booster sessions, potentially reducing the frequency of clinic visits while maintaining benefits.
Troches are prescribed only after confirming IV ketamine provides meaningful benefit for your OCD symptoms. We start with conservative dosing and adjust based on your response and tolerability.
Ketamine combined with therapeutic processing may enhance outcomes beyond medication alone. The medication creates temporary windows of reduced obsessive thoughts when your brain is more receptive to forming new patterns and engaging with therapeutic work that normally feels overwhelming.
During these sessions, you work with therapeutic support to process underlying patterns, develop healthier responses to intrusive thoughts, and build skills for managing OCD outside the ketamine state. The enhanced neuroplasticity during ketamine sessions may help consolidate therapeutic learning in ways that persist after the medicine’s acute effects fade.
The frequency and structure of these sessions depends on your individual needs, symptom severity, and response to treatment. Some patients benefit from intensive work during the period of peak ketamine response, while others use a less frequent maintenance approach.
OCD often manifests with significant body-based symptoms—chronic muscle tension from constant vigilance, difficulty relaxing, compulsive physical rituals, and dysregulated nervous system patterns. Somatic facilitation during ketamine sessions addresses these body-level dimensions through breath work, sensation tracking, movement, and nervous system regulation.
Your facilitator guides attention to physical sensations and autonomic states arising during treatment. You learn to work directly with your nervous system’s activation patterns rather than only cognitive strategies. This body-centered approach can access aspects of OCD that don’t respond to talk-based interventions alone.
Many people with OCD experience their symptoms as much in their body as their mind—the physical urge to perform rituals, the somatic anxiety preceding compulsions, the bodily relief following completion. Somatic work addresses these embodied patterns directly.
Comprehensive psychiatric medication management remains essential whether or not ketamine provides benefit. We evaluate your current medication regimen, ensure you’ve had adequate trials of appropriate medications at therapeutic doses, make evidence-based adjustments to optimize your treatment, and coordinate with your other providers.
Many patients haven’t received truly optimal medication management before considering ketamine. We take time to ensure first-line treatments are maximized. For some patients, sophisticated medication adjustments may provide more benefit than adding ketamine.
Ketamine doesn’t replace standard OCD medications—it’s used alongside them as an adjunctive strategy. We continue medication management throughout ketamine treatment, monitoring for interactions and adjusting your regimen as symptoms change.
Response to ketamine in OCD is variable and often modest compared to ketamine’s effects in depression or PTSD. Research suggests approximately 25-50% of treatment-resistant OCD patients experience meaningful symptom reduction, with effects typically lasting 1-3 weeks after single infusions.
When response occurs, the onset is striking—patients describe obsessive thoughts suddenly lifting during the infusion itself. However, symptoms typically return gradually over subsequent days to weeks. Repeated infusions or maintenance protocols may extend benefits, though optimal schedules for OCD remain uncertain.
Not all OCD patients respond equally. Patients with primarily constant intrusive thoughts may respond better than those with mainly behavioral compulsions. Your specific symptom profile, severity, treatment history, and neurobiological factors all influence whether ketamine will help.
It’s important to maintain realistic expectations. Ketamine is not a standard OCD treatment, may not work for your specific symptoms, provides temporary rather than permanent relief when effective, requires ongoing maintenance if beneficial, and works best as part of comprehensive care including appropriate medications.
The evidence for ketamine in OCD remains preliminary. You’re pursuing an adjunctive treatment with limited research support compared to conditions like depression where ketamine’s benefits are well-established.
Ketamine for OCD may be appropriate for adults with severe, treatment-resistant OCD who have tried multiple adequate medication trials without sufficient response, experience significant functional impairment from symptoms, have primarily constant intrusive thoughts as a prominent feature, and understand the preliminary nature of evidence supporting this use.
This treatment is not appropriate as first-line intervention, when standard treatments haven’t been adequately tried, when expecting ketamine to provide cure or permanent relief, or without commitment to comprehensive medication management and therapeutic work alongside ketamine.
You should have realistic expectations about likely outcomes, understand that you’re pursuing an adjunctive treatment with preliminary evidence, and be prepared for the possibility that ketamine may not help your specific OCD presentation.
Living with treatment-resistant OCD is exhausting and demoralizing. When standard treatments don’t provide adequate relief, exploring additional options becomes important. While ketamine isn’t a proven OCD treatment, emerging evidence suggests it may offer benefit for some patients as part of comprehensive care.
Our practice provides psychiatric expertise and ketamine therapy in a medically supervised, safe environment. We’re transparent about what we can offer, honest about evidence limitations, and committed to helping you find the most effective treatment approach for your individual situation.
[1] Rodriguez, C.I., et al. (2013). “Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept.” Neuropsychopharmacology, 38(12), 2475-2483.
https://www.nature.com/articles/npp2013150
[2] Sharma, L.P., et al. (2020). “Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder.” Asian Journal of Psychiatry, 52, 102183.
https://www.sciencedirect.com/science/article/abs/pii/S1876201820302951
Conditions Treated
1201 U.S. Highway 10 W, Unit A4, Livingston 59047
Mend The Mind is a psychiatric practice in Livingston, Montana, specializing in ketamine therapy and comprehensive mental health services for adults. With anesthesia expertise ensuring the highest safety standards, we bring evidence-based treatment to rural Montana communities.